The contractor shall utilize nanoparticles to deliver the mper-based immunogens to elicit bnabs against the mper of HIV-1 GP41 to develop a protective vaccine against the virus.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93021C00026
- Awardee
-
Neovaxsyn Inc. UEI EHMTBALCKFE8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proprosals Pre-Solicitation · SBIRPHS20211 · Posted Jul 9, 2020
- Nannovaccine for Eliciting 10E8-like bnAbs against HIV-1 Award Notice · Posted Jul 2, 2021
- Contract value 100% obligated
- $300,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 4 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Ames, IA 50014, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $300,000 |
Show all 13
About this award
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small Business Innovation Research (SBIR) program, which has a total small business set-aside designation. Neovaxsyn Inc. conducts infectious disease research and development, including work on HIV/AIDS vaccines, and has received prior federal contracts and grants from NIAID and other Department of Health and Human Services agencies.
Quick answers
Who was awarded contract 75N93021C00026?
75N93021C00026 was awarded to Neovaxsyn Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2021.
How much is contract 75N93021C00026 worth?
The government has obligated $300,000 on 75N93021C00026.
Was contract 75N93021C00026 competed?
The extent of competition for 75N93021C00026 was full and open competition after exclusion of sources. The government received 4 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award